Pfizer Inc. (PFE)
Pfizer's Diverse Portfolio And Strong Execution Earn Analyst Praise Despite Patent Concerns
On Tuesday, Pfizer Inc. PFE reported second-quarter adjusted EPS of $0.60, down 11% year over year, beating the consensus of $0.46.
Merck / Pfizer Earnings Summaries: Staying With Merck For Now, Pfizer's Cost-Cutting Will Help Margins
The prime culprit for yesterday's 9.8% drop in Merck was what seemed to be a rather slight slip in Gardasil revenue – Merck's HPV vaccine – which came in about $20 million below consensus. At $113 – $115 per share, MRK is now trading at 14x and 12x 2024 and 2025 consensus estimates for expected growth this year that compares to '22 $7.48 in EPS. Pfizer reported a good quarter yesterday, with a 2% revenue beat and a 30% EPS for y-o-y growth of 2%, 9% operating income growth and -2% decline in EPS.
Pfizer Posts First Quarterly Revenue Growth Since Peak COVID Vaccine Sales
Pfizer (PFE) shares rose Tuesday after the pharmaceutical giant beat second-quarter revenue expectations and raised its full-year guidance.
Stock Of The Day: Pfizer Pattern Offers Lessons After Better-Than-Expected Q2 Results
Like many things on Wall Street, technical analysis is widely misunderstood. Many analysts try to identify chart patterns without understanding the psychology and price action that creates them.
Pfizer (PFE) Beats on Q2 Earnings & Sales, Raises 2024 View
Pfizer (PFE) beats second-quarter estimates for earnings and sales. It raises 2024 earnings as well as revenue expectations.
Here's What Key Metrics Tell Us About Pfizer (PFE) Q2 Earnings
The headline numbers for Pfizer (PFE) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Pfizer (PFE) Tops Q2 Earnings and Revenue Estimates
Pfizer (PFE) came out with quarterly earnings of $0.60 per share, beating the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.67 per share a year ago.
Pfizer Stock Rises After Guidance Hike, Earnings Beat.
Drugmaker Pfizer reported quarterly earnings above expectations on Tuesday as it raised full year guidance on the back of strong sales of non-Covid products.
Pfizer upgrades guidance; on track to deliver $4bn of net cost savings
Pfizer Inc's (NYSE:PFE, ETR:PFE) stock is up ahead of the bell after the company raised its annual profit forecast following stronger-than-expected sales of its Covid vaccine and antiviral treatment. The drugmaker now anticipates an annual profit of $2.45 to $2.65 per share, up from its previous forecast of $2.15 to $2.35 per share.
Pfizer Beats Q2 Estimates, Boosts 2024 Outlook
Pfizer's Q2 revenue reaches $13.28 billion, marking a 2% increase year-over-year and surpassing projected $12.96 billion
Pfizer Stock Rises On Earnings Beat, Raised Outlook
Pfizer beat second-quarter views and guided up for the full year. Pfizer stock, already in a buy zone, rose Tuesday.
Pfizer beats earnings estimates, hikes full-year outlook as drugmaker cuts costs
Pfizer reported second-quarter revenue and adjusted earnings that blew past expectations and raised its full-year outlook as the drugmaker works to slash costs. The results come as Pfizer scrambles to stabilize its business and win back Wall Street's favor following the rapid decline in demand for its Covid products.
